テルイ ヤスヒト
TERUI Yasuhito
照井 康仁 所属 埼玉医科大学 医学部 血液内科 職種 教授 |
|
論文種別 | 学術雑誌(原著) |
言語種別 | 英語 |
査読の有無 | 査読あり |
表題 | Safety and pharmacokinetics of polatuzumab vedotin in Japanese patients with relapsed/refractory B-cell non-Hodgkin lymphoma: a phase 1 dose-escalation study |
掲載誌名 | 正式名:Jpn J Clin Oncol ISSNコード:14653621 |
掲載区分 | 国外 |
巻・号・頁 | 51,70-77頁 |
著者・共著者 | Kinoshita, T., Hatake, K., Yamamoto, K., Higuchi, Y., Murakami, S., Terui, Y., Yokoyama, M., Maruyama, D., Makita, S., Hida, Y., Saito, T., Tobinai, K. |
発行年月 | 2021 |
概要 | Patients received pola (1.0 or 1.8 mg/kg) intravenously every 21 days until disease progression or intolerance. Intra-patient dose escalation was prohibited. Tolerability was determined by the standard 3 + 3 rule. Blood sampling was performed to characterize pharmacokinetics. Four patients received pola 1.0 mg/kg; three received 1.8 mg/kg. Patients had follicular lymphoma (n = 4) or diffuse large B-cell lymphoma (n = 3), median age of 62 years, received a median of 3 prior therapies; six were female. Pola was well tolerated in both cohorts, with no dose-limiting toxicities observed. The most common adverse event was peripheral sensory neuropathy (n = 4). Grade 3 adverse events were cholecystitis and neutrophil count decreased (one each; both 1.0 mg/kg), and syncope and cataract (one each; both 1.8 mg/kg). The plasma half-life of antibody-conjugate monomethyl auristatin E was 4.43-7.98 days, and systemic exposure of unconjugated monomethyl auristatin E was limited in both cohorts. |
DOI | 10.1093/jjco/hyaa169 |
文献番号 | 33029633 |